GYRE Subsidiary Submits New Drug Application for Lead Candidate F351 (Hydronidone) in China

summarizeSummary

Gyre Therapeutics' subsidiary submitted a New Drug Application (NDA) for its lead product candidate, F351 (Hydronidone), in China for chronic hepatitis B-induced liver fibrosis.

check_boxKey Events

• NDA Submission for Lead Candidate

  Gyre Pharmaceuticals Co., Ltd., a majority indirectly owned subsidiary of Gyre Therapeutics, Inc., submitted a New Drug Application (NDA) to the Center for Drug Evaluation (CDE) of China's National Medical Products Administration for F351 (Hydronidone).

• Targeting Liver Fibrosis in China

  The NDA seeks approval for F351 (Hydronidone) for the treatment of chronic hepatitis B (CHB)-induced liver fibrosis, addressing a significant medical need in the Chinese market.

• Advancing Regulatory Pathway

  This submission represents a critical regulatory milestone for the company's lead product candidate, following previously reported successful Phase 3 clinical trial results.

• Initiation of Review Process

  The NDA will undergo initial formatting and completeness verification, with the company anticipating an acceptance number from the CDE before the technical review process begins.

auto_awesomeAnalysis

This 8-K reports a significant regulatory milestone for Gyre Therapeutics. The submission of a New Drug Application (NDA) for F351 (Hydronidone), the company's lead product candidate, in China for chronic hepatitis B-induced liver fibrosis, marks a critical step towards potential commercialization. This follows the successful Phase 3 results for Hydron previously detailed in the company's 10-K filed on March 13, 2026. While regulatory approval is not guaranteed and the process is subject to CDE review, the NDA submission itself de-risks the development pathway and provides a clear path forward for the drug in a major market.